United Therapeutics Corp

UTHR trades at a P/E of 18.73 against a pharma backdrop where valuations have compressed, yet the stock sits 54.8 on RSI—precisely neutral territory with zero overbought pressure. The 7.49% short interest is modest, suggesting minimal squeeze catalyst lurking. At $25.1B market cap, this isn't a micro-cap story, but the neutral momentum reading combined with a reasonable valuation multiple hints the market hasn't fully priced in either upside conviction or downside fear. The absence of extremes—not at 52-week highs, RSI in the dead center—implies equilibrium pricing where catalysts matter more than technical exhaustion.